Cardlytics (CDLX) Reports Q2 Loss, Misses Revenue Estimates

Cardlytics (CDLX) reported a Q2 2025 adjusted loss of $0.13 per share, outperforming the Zacks Consensus Estimate of a $0.16 loss and an improvement from the $0.15 loss a year prior. However, quarterly revenues of $63.25 million missed consensus estimates by 0.86% and declined year-over-year from $69.64 million. Despite consistently exceeding EPS estimates over the past four quarters, CDLX shares have significantly underperformed the S&P 500 year-to-date, declining 50.4%. Future stock movement will largely depend on management's commentary during the earnings call, with the stock currently holding a Zacks Rank #3 (Hold).

Analysis

Cardlytics (CDLX) reported mixed results for its second quarter, characterized by a notable divergence between bottom-line performance and top-line trends. The company posted an adjusted loss of $0.13 per share, which represents an 18.75% positive earnings surprise by beating the Zacks Consensus Estimate of a $0.16 loss and improving upon the $0.15 loss from the prior-year quarter. This marks the fourth consecutive quarter CDLX has surpassed EPS estimates. However, this profitability beat is contrasted by a weak revenue figure of $63.25 million, which missed consensus estimates by 0.86% and, more critically, reflects a 9.2% year-over-year decline from $69.64 million. This top-line erosion is a significant concern, especially when viewed against the backdrop of the stock's severe underperformance, having lost 50.4% year-to-date while the S&P 500 gained 7.1%. The current Zacks Rank #3 (Hold) rating suggests the market anticipates the stock will perform in line with the market, but the future trajectory will heavily depend on management's forthcoming commentary and subsequent revisions to earnings estimates.

Key Decisions for Investors

• Investors should scrutinize management's commentary on the earnings call for a clear strategy to reverse the top-line decay, as the recurring EPS beats are being overshadowed by declining year-over-year revenue.
• Given the stock's 50.4% year-to-date decline, the positive EPS surprise may not be a sufficient catalyst for a sustained rally; consider the revenue miss and YoY decline as primary indicators of fundamental health.
• The Zacks #3 (Hold) rating implies a neutral short-term outlook, making it prudent to monitor for any post-earnings revisions to consensus estimates before altering a position, as the current mixed signals offer no clear directional conviction.